The United States and the European Union are set to begin issuing a list of more than 100 drugs in the second half of this year that contain cholinergic substances.
The announcement was made during a conference on drug policy hosted by the Council on Foreign Relations, a Washington-based think tank.
According to the list, published Thursday by the Institute of Medicine, cholinergics are listed under drugs known as novel drugs, which means they are not covered by existing FDA drug policies.
The institute says the drugs may be included on the list as a result of the Trump administration’s announcement on Tuesday to move forward with a review of existing U.N. regulations.
The list also contains other novel drugs.
Among the drugs are an antiviral drug called ZaVu that is being evaluated by the FDA for use in malaria prevention, a novel antihistamine called Gleevec that has received approval in South Africa and an antivirus drug called Staphylococcus aureus that is approved in China and India, according to the institute.
The institute is expected to release its recommendations later this year.
The White House announced on Wednesday that President Donald Trump would be rolling back the Obama administration’s ban on sales of Chloroquine, an antipyretic drug used to treat malaria.
Chloroquines were originally approved by the Trump administrations predecessor, President Barack Obama.
But the White House said it would be taking another step to allow Chlorodilators to be sold in the United States.
The administration said it was “grateful” to the FDA and other health agencies for their efforts to curb the spread of the disease, and that it was reviewing the current ChloroSucru and Chloro-Bac drugs to make sure they were safe and effective.